Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide vs Glimepiride on Cardiovascular Risk Markers in Type 2 Diabetes
NCT01593137Phase 4Withdrawn
- Sponsor
- Fundación Fernández-Cruz
- Start
- May 2012
- Primary completion
- Dec 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Fundación Fernández-Cruz. Planned start May 2012; status: withdrawn.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01593137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01593137.